• Welcome
  • The Board
  • Our Investors
  • soloMER Technology
  • Licensing Opportunities
  • Pipeline
  • Publications
  • Contact
  • News
ELASMOGEN
Elasmogen CEO Caroline Barelle Interviewed by Life Sciences Scotland for Leadership Insight

Elasmogen CEO Caroline Barelle Interviewed by Life Sciences Scotland for Leadership Insight

by elasmogen | Jan 30, 2019 | News

Life Sciences Scotland have interviewed Elasmogen’s CEO Caroline Barelle as part of their Insight series. The article can be accessed here.
Elasmogen Licenses NDure™ Half-life Extension Technology to ImmunoForge

Elasmogen Licenses NDure™ Half-life Extension Technology to ImmunoForge

by elasmogen | Jan 7, 2019 | News

Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019:  Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement...

News archives

  • May 2025
  • March 2025
  • December 2024
  • June 2024
  • April 2024
  • November 2023
  • June 2023
  • May 2023
  • April 2023
  • December 2022
  • September 2022
  • May 2022
  • December 2021
  • September 2021
  • January 2021
  • December 2020
  • July 2020
  • May 2020
  • April 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • July 2019
  • May 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • May 2018
  • January 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • August 2016
  • July 2016
  • March 2016
  • December 2015
  • Follow
welcome
the board
our investors
soloMER® technology
licensing opportunities
pipeline
publications
contact
news

Liberty Building
Foresterhill Health Campus
Foresterhill Rd
Aberdeen AB25 2ZP

t: (+44) 070 7721 0755